Perrigo Co. PLC isn't abandoning its tried-and-true focus on OTC drugs, but its strategic view is expanding from private label and store brand products to include a national brand in its first potential US Rx-to-OTC switch.
The Dublin-headquartered firm announced Aug. 9 that it has licensed exclusive US rights to develop and market an OTC version of Merck & Co. Inc.'s Nasonex Nasal Spray as...